Compare Pfizer Inc (PFE) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Raymond James Financial, Inc. — how do they compare? Pfizer Inc trades at $27.71 (market cap $158.56B), while Raymond James Financial, Inc. trades at $158.14 (market cap $30.51B). The key difference: Pfizer Inc is far larger — about 5.2× Raymond James Financial, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Raymond James Financial, Inc. for 74 Days on average.
| PFE | RJF | |
|---|---|---|
Market Cap | $158.56B | $30.51B |
Volume | 44,138,282 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $29.02 | $181.18 |
52-Week Low | $23.67 | $140.89 |
Typical Hold Time | 158 Days | 74 Days |
Enterprise Value | $210.06B | $24.37B |
Dividend Yield | 6.18% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Raymond James Financial (RJF) trades at $157.29, down 1.4% with a bearish technical signal. The company shows strong fundamentals with consistent earnings beats, 15.4% net margin, and 18.5% ROE. Recent Q3 2026 results featured record revenues of $3.93 billion, beating estimates. Analysts maintain a Hold consensus with $184 price target, representing 17% upside potential from current levels.
RJF presents a mixed outlook with strong operational performance offset by technical weakness. The stock offers value at 13.7x P/E with dividend growth potential, but faces headwinds from rising expenses and market volatility. Institutional activity shows mixed signals with both position increases and decreases among major holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
